|

Treatment and Prognosis of Patients With Chronic HBV Infection

RECRUITINGSponsored by Xiangya Hospital of Central South University
Actively Recruiting
SponsorXiangya Hospital of Central South University
Started2021-10-25
Est. completion2024-10-25
Eligibility
Age18 Years – 79 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05392387

Summary

Hepatitis B virus (HBV) infection is a major global health issue with 257 million chronically infected individuals. Of note, China has the largest population accounting for one third of the world's infected population. Approximately, about 300 000 people die each year due to the consequences of HBV. In 2016, the World Health Organization (WHO) proposed the goal for elimination of hepatitis B as public health threat by 2030 and China will be a major contributor towards this global goal. Currently, two approved therapeutic strategies are available including pegylated interferon (IFN) or nucleos (t) ide analogues (NA), which could suppress HBV replication and slow disease progression. Here, investigators hope to launch a cohort study to reveal the clinical features relating to therapeutic efficacy of antiviral therapy and the prognosis of patients with differential therapeutic strategies.

Eligibility

Age: 18 Years – 79 YearsHealthy volunteers accepted
Inclusion Criteria:

patients with evidence of chronic HBV infection

Exclusion Criteria:

chronic liver injury mainly caused by other reasons, such as autoimmune diseases, alcohol, drugs and so on.

Conditions2

Hepatitis B Virus InfectionLiver Disease

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.